Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury.

Cell division autoantigen 1 (CDA1) enhances TGF-β signaling in renal and vascular cells, and renal expression of CDA1 is elevated in animal models of diabetes. In this study, we investigated the genetic deletion of Tspyl2, the gene encoding CDA1, in C57BL6 and ApoE knockout mice. The increased renal expression of TGF-β1, TGF-β type I and II receptors, and phosphorylated Smad3 associated with diabetes in wild-type mice was attenuated in diabetic CDA1 knockout mice. Notably, CDA1 deletion significantly reduced diabetes-associated renal matrix accumulation and immunohistochemical staining for collagens III and IV and attenuated glomerular and tubulointerstitial injury indices, despite the presence of persistent hyperglycemia, polyuria, renal hypertrophy, and hyperfiltration. Furthermore, CDA1 deletion reduced gene expression of TGF-β1 receptors in the kidney, resulting in a functionally attenuated response to exogenous TGF-β, including reduced levels of phosphorylated Smad3 and ERK1/2, in primary kidney cells from CDA1 knockout animals. Taken together, these data suggest that CDA1 deletion reduces but does not block renal TGF-β signaling. Because direct antagonism of TGF-β or its receptors has unwanted effects, CDA1 may be a potential therapeutic target for retarding DN and perhaps, other kidney diseases associated with TGF-β-mediated fibrogenesis.

[1]  R. Grimley,et al.  Identification of Novel Interacting Partners of Sirtuin6 , 2012, PloS one.

[2]  K. Kuwano,et al.  Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-induced senescence of human bronchial epithelial cells. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[3]  M. Cooper,et al.  Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy. , 2011, Kidney international.

[4]  M. Cooper,et al.  Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-β in a murine diabetic model of atherosclerosis , 2009, Diabetologia.

[5]  Merlin C. Thomas,et al.  Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes , 2008, Diabetes.

[6]  M. V. Dinther,et al.  Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. , 2008, Kidney international.

[7]  M. Kretzler,et al.  From Fibrosis to Sclerosis Mechanisms of Glomerulosclerosis in Diabetic , 2008 .

[8]  N. Laping,et al.  Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. , 2007, American journal of physiology. Renal physiology.

[9]  R. Foley,et al.  End-stage renal disease in the United States: an update from the United States Renal Data System. , 2007, Journal of the American Society of Nephrology : JASN.

[10]  M. Zhang,et al.  ERK, p38, and Smad signaling pathways differentially regulate transforming growth factor-beta1 autoinduction in proximal tubular epithelial cells. , 2006, The American journal of pathology.

[11]  Merlin C. Thomas,et al.  Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. , 2006, Journal of the American Society of Nephrology : JASN.

[12]  J. Egido,et al.  Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-β–Independent Mechanism , 2005, Circulation.

[13]  M. Cooper,et al.  Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. , 2005, Journal of the American Society of Nephrology : JASN.

[14]  Merlin C. Thomas,et al.  Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. , 2004, Journal of the American Society of Nephrology : JASN.

[15]  E. Bottinger,et al.  Utility of endogenous creatinine clearance as a measure of renal function in mice. , 2004, Kidney international.

[16]  L. Truong,et al.  Advanced glycation end products activate Smad signaling via TGF‐β‐dependent and ‐independent mechanisms: implications for diabetic renal and vascular disease , 2004 .

[17]  R. Atkins,et al.  Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. , 2004, Kidney international.

[18]  L. Truong,et al.  Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  F. Ziyadeh,et al.  Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. , 2003, Seminars in nephrology.

[20]  J. Egido,et al.  Connective Tissue Growth Factor Is a Mediator of Angiotensin II–Induced Fibrosis , 2003, Circulation.

[21]  Hong-Jian Zhu,et al.  Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. , 2003, Kidney international.

[22]  N. Wahab,et al.  J Am Soc Nephrol 14: 1358–1373, 2003 Extracellular Matrix Metabolism in Diabetic Nephropathy , 2022 .

[23]  C. Tsalamandris,et al.  Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. , 2002, Diabetes care.

[24]  R. Atkins,et al.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.

[25]  A. Mawson,et al.  SET-related Cell Division Autoantigen-1 (CDA1) Arrests Cell Growth* , 2001, The Journal of Biological Chemistry.

[26]  M. Goumans,et al.  Abnormal angiogenesis but intact hematopoietic potential in TGF‐β type I receptor‐deficient mice , 2001, The EMBO journal.

[27]  K. Sharma,et al.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  F. Locatelli,et al.  End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  M. Cooper,et al.  A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). , 1998, Kidney international.

[30]  A. Kulkarni,et al.  Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. , 1995, Development.

[31]  A. Kulkarni,et al.  Immune dysregulation in TGF-beta 1-deficient mice. , 1994, Journal of immunology.

[32]  A. Kulkarni,et al.  Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. , 1993, The American journal of pathology.

[33]  E Ruoslahti,et al.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Sporn,et al.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.